For Immediate Release
Chicago, IL – November 15, 2011 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include WellPoint Inc. ( , UnitedHealth Group Inc. ( (UNH - Analyst Report), Aetna Inc. ( (AET - Analyst Report), HealthSpring Inc. ( and Cigna Corp. ( (CI - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Insurance Major Eyes Acquisition
Media reports revealed that XL Health Corp. is being chased by WellPoint Inc. ( , UnitedHealth Group Inc. ( (UNH - Analyst Report) and Aetna Inc. ( (AET - Analyst Report), as each of these big insurers are eyeing the company’s Medicare Advantage business, which is expected to grow overwhelmingly over the next five years.
It is also reported that the purchase consideration may range between $1.5 billion and $2 billion for Matlin Patterson Global Advisers owned XLHealth Corp., a provider of managed care for chronically ill Medicare members.
The acquisition of XLHealth Corp. will follow the similar strategic acquisition of HealthSpring Inc. ( by Cigna Corp. ( (CI - Analyst Report) for $3.8 billion in late October.
Rationale of the Acquisition
A Medicare Advantage Plan is offered by private health insurance companies for the elderly and disabled.
The first baby boomers will hit their retirement ages soon and will opt for managed care plans. Health Insurers will thus look to acquire providers of managed care plans which in turn will help them generate higher revenues.
Also, according to reports, managed-care plans for Medicare, the U.S. health program for the elderly and disabled will generate incremental revenue of $10 billion by 2015, which would justify such acquisitions.
The companies earlier have acquired providers of chronically ill coverage. Brentwood-based Inspiris was acquired by UnitedHealth in March 2011 while CareMore Health Group was purchased by WellPoint in June 2011.
Capital Position of Prospective Acquirers
UnitedHealth Group ended the third quarter with cash and cash equivalents of $13.7 billion, almost a 50% increase over 2010 level. Year to date cash from operation totaled $7.4 billion, a 53% year-over -year increase.
Aetna exited the third quarter with cash and cash equivalents of $1.9 billion, a 5% increase over the 2010 level. Year- to -date, cash from operations totaled $2 billion, a whopping year-over- year increase of 138%.
WellPoint exited the quarter with cash and cash equivalents of $2.5 billion, an increase of 39% from 2010 end level. Year-to-date, operating cash flows totaled $3.3 billion, up 300% year over year.
The companies’ solid capital position will enable it to fund the acquisition once it materializes.
Earnings Recap of Prospective Acquirers
Aetna has posted third quarter 2011 earnings of $1.40 per share, significantly ahead of the Zacks Consensus Estimate of $1.14 as well as the year-ago quarter’s earnings of $1.00.
Declining utilization, strong performance across all the product lines, disciplined pricing and medical cost trends accounted for the earnings upside.
WellPoint reported third-quarter adjusted income of $1.77 per share, striding ahead of the Zacks Consensus Estimate of $1.69. Results were also 1.7% higher than $1.74 earned in the year-ago quarter.
The quarter benefited from improved membership growth and a decline in selling, general and administrative expenses.
UnitedHealth reporting third quarter earnings of $1.17 per share, higher than the Zacks Consensus estimate of $1.12. Earnings also compared favorably with $1.14 reported in the prior-year quarter.
The out-performance was driven by strong revenue growth from UnitedHealthcare, as well as from the Optum businesses, partially offset by higher medical cost.
The quantitative Zacks #1 Rank (short-term Strong Buy rating) for Aetna Inc. indicates upward pressure on the stock over the near term.
The quantitative Zacks #2 Rank (short-term Buy rating) for WellPoint indicates upward pressure on the stock over the near term.
The quantitative Zacks #3 Rank (short-term Hold rating) for UnitheHealth indicates no clear directional pressure on the stock over the near term.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339